Search Results

There are 15257 results for: content related to: Prediction of overall survival or progression free survival by disease control rate at week 8 is independent of ethnicity: Western versus Chinese patients with first-line non-small cell lung cancer treated with chemotherapy with or without bevacizumab

  1. Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms

    The Journal of Clinical Pharmacology

    Volume 54, Issue 5, May 2014, Pages: 495–502, Mitsukuni Suenaga, Nozomu Fuse, Tatsuro Yamaguchi, Yasuhiro Yamanaka, Shigeki Motomura, Hiroshi Matsumoto, Yasuo Hamamoto, Nobuyuki Mizunuma, Toshihiko Doi, Kiyohiko Hatake, Junko Iwasaki and Atsushi Ohtsu

    Version of Record online : 2 JAN 2014, DOI: 10.1002/jcph.246

  2. You have full text access to this OnlineOpen article
    Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer

    The Journal of Clinical Pharmacology

    Volume 56, Issue 8, August 2016, Pages: 966–973, Michelle A. Rudek, Arvind Dasari, Daniel Laheru, Ping He, Runyan Jin, Rosalind Walker, Gretchen E. Taylor, Antonio Jimeno, Ross C. Donehower, Manuel Hidalgo, Wells A. Messersmith and W. Thomas Purcell

    Version of Record online : 2 FEB 2016, DOI: 10.1002/jcph.681

  3. Beyond peptides and mAbs—current status and future perspectives for biotherapeutics with novel constructs

    The Journal of Clinical Pharmacology

    Volume 55, Issue S3, March 2015, Pages: S4–S20, Dalal AlDeghaither, Brandon G. Smaglo and Louis M. Weiner

    Version of Record online : 23 FEB 2015, DOI: 10.1002/jcph.407

  4. You have free access to this content
    Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas

    Cancer

    Volume 116, Issue 17, 1 September 2010, Pages: 3988–3999, Marc C. Chamberlain

    Version of Record online : 19 AUG 2010, DOI: 10.1002/cncr.25256

  5. Reporting of serious adverse events during cancer clinical trials to the institutional review board: An evaluation by the Research on Adverse Drug events And Reports (RADAR) project

    The Journal of Clinical Pharmacology

    Volume 53, Issue 12, December 2013, Pages: 1334–1340, S.M. Belknap, C.H. Georgopoulos, J. Lagman, S.A. Weitzman, L. Qualkenbush, P.R. Yarnold, B.J. Edwards, J.M. McKoy, S.M. Trifilio and D.P. West

    Version of Record online : 25 SEP 2013, DOI: 10.1002/jcph.177

  6. Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases

    British Journal of Surgery

    Volume 98, Issue 3, March 2011, Pages: 399–407, D. A. Wicherts, R. J. de Haas, M. Sebagh, E. Saenz Corrales, D. L. Gorden, F. Lévi, B. Paule, D. Azoulay, D. Castaing and R. Adam

    Version of Record online : 15 DEC 2010, DOI: 10.1002/bjs.7368

  7. Retina, Vitreous

    Clinical & Experimental Ophthalmology

    Volume 36, Issue s1, June 2008, Pages: A459–A584,

    Version of Record online : 18 JUL 2008, DOI: 10.1111/j.1442-9071.2008.01760.x

  8. You have free access to this content
    Anti-vascular endothelial growth factor for neovascular age-related macular degeneration

    Intervention Review

    The Cochrane Library

    Sharon D Solomon, Kristina Lindsley, Satyanarayana S Vedula, Magdalena G Krzystolik and Barbara S Hawkins

    Published Online : 29 AUG 2014, DOI: 10.1002/14651858.CD005139.pub3

  9. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer

    Intervention Review

    The Cochrane Library

    Anna Dorothea Wagner, Christoph Thomssen, Johannes Haerting and Susanne Unverzagt

    Published Online : 11 JUL 2012, DOI: 10.1002/14651858.CD008941.pub2

  10. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model

    Journal of Evaluation in Clinical Practice

    Volume 18, Issue 2, April 2012, Pages: 247–255, Jignesh J. Patel, Margaret A.S. Mendes, Mark Bounthavong, Melissa L.D. Christopher, Daniel Boggie and Anthony P. Morreale

    Version of Record online : 16 SEP 2010, DOI: 10.1111/j.1365-2753.2010.01546.x

  11. You have free access to this content
    Early vitreoretinal surgery on vascularly active stage 4 retinopathy of prematurity through the preoperative intravitreal bevacizumab injection

    Acta Ophthalmologica

    Volume 91, Issue 4, June 2013, Pages: e304–e310, Yu Xu, Qi Zhang, Xiaoli Kang, Ying Zhu, Jiakai Li, Yiye Chen and Peiquan Zhao

    Version of Record online : 7 MAY 2013, DOI: 10.1111/aos.12055

  12. Complementary effects of bevacizumab and MMC in the improvement of surgical outcome after glaucoma filtration surgery

    Acta Ophthalmologica

    Volume 93, Issue 7, November 2015, Pages: 667–678, Tine Van Bergen, Evelien Vandewalle, Lieve Moons and Ingeborg Stalmans

    Version of Record online : 18 MAY 2015, DOI: 10.1111/aos.12766

  13. You have free access to this content
    Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab

    Cancer

    Volume 121, Issue 9, May 1, 2015, Pages: 1456–1462, Jim Zhong, Arif N. Ali, Alfredo D. Voloschin, Yuan Liu, Walter J. Curran Jr, Ian R. Crocker and Hui-Kuo G. Shu

    Version of Record online : 29 DEC 2014, DOI: 10.1002/cncr.29234

  14. Anti-angiogenic therapies for metastatic colorectal cancer

    Intervention Review

    The Cochrane Library

    Anna Dorothea ADW Wagner, Dirk Arnold, Axel AG Grothey, Johannes Haerting and Susanne Unverzagt

    Published Online : 8 JUL 2009, DOI: 10.1002/14651858.CD005392.pub3

  15. You have free access to this content
    Bevacizumab and glioblastoma: Scientific review, newly reported updates, and ongoing controversies

    Cancer

    Volume 121, Issue 7, April 1, 2015, Pages: 997–1007, Kathryn M. Field, Justin T. Jordan, Patrick Y. Wen, Mark A. Rosenthal and David A. Reardon

    Version of Record online : 26 SEP 2014, DOI: 10.1002/cncr.28935

  16. Management of glioblastoma: comparison of clinical practices and cost-effectiveness in two cohorts of patients (2008 versus 2004) diagnosed in a French university hospital

    Journal of Clinical Pharmacy and Therapeutics

    Volume 39, Issue 6, December 2014, Pages: 642–648, G. Diebold, F. Ducray, A.-M. Henaine, D. Frappaz, J. Guyotat, S. Cartalat-Carel, V. Breant, A. Fouquet, G. Aulagner, J. Honnorat and X. Armoiry

    Version of Record online : 28 AUG 2014, DOI: 10.1111/jcpt.12199

  17. Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study

    Pharmacoepidemiology and Drug Safety

    Volume 23, Issue 7, July 2014, Pages: 726–734, Axel Grothey, E. Dawn Flick, Allen L. Cohn, Tanios S. Bekaii-Saab, Johanna C. Bendell, Mark Kozloff, Nancy Roach, Yong Mun, Susan Fish and Herbert I. Hurwitz

    Version of Record online : 16 MAY 2014, DOI: 10.1002/pds.3633

  18. Angiogenesis inhibitors for the treatment of ovarian cancer

    Intervention Review

    The Cochrane Library

    Kezia Gaitskell, Igor Martinek, Andrew Bryant, Sean Kehoe, Shibani Nicum and Jo Morrison

    Published Online : 7 SEP 2011, DOI: 10.1002/14651858.CD007930.pub2

  19. You have free access to this content
    Bevacizumab modulates epithelial-to-mesenchymal transition in the retinal pigment epithelial cells via connective tissue growth factor up-regulation

    Acta Ophthalmologica

    Volume 90, Issue 5, August 2012, Pages: e389–e398, Ching-Long Chen, Chang-Min Liang, Yi-Hao Chen, Ming-Cheng Tai, Da-Wen Lu and Jiann-Torng Chen

    Version of Record online : 19 JUN 2012, DOI: 10.1111/j.1755-3768.2012.02426.x

  20. Bevacizumab (Avastin)

    Handbook of Therapeutic Antibodies

    Eduardo Díaz-Rubio, Edith A. Perez, Guiseppe Giaccone, Pages: 779–812, 2008

    Published Online : 1 FEB 2008, DOI: 10.1002/9783527619740.ch29